Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This project aims to define mechanisms through which varenicline might be an effective smoking cessation medication.
Full description
Thirty treatment seeking smokers will be recruited to complete a 40-day within-subject (cross-over), double-blind study that will assess effects of varenicline on brain activation while performing certain tasks. Prior to beginning the study, participants will complete an health and physical screening to determine final eligibility. Following a medication run-up and a 3.5 day abstinence period, participants will complete study period 1 (an fMRI scan while performing attention, working memory and emotion tasks). After a 14 to 21-day washout period the study procedures will be repeated with placebo (order of study medication counterbalanced). After completion of both study periods, all participants will be offered a 13-week quit smoking program with varenicline.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Smoking Behavior
Alcohol/Drug Exclusion Criteria
Medication Exclusion Criteria
Prior use of Chantix
Current use or recent discontinuation (within last 14-days) of the following medications:
Any form of smoking cessation medication
Any form of anti-psychotic medications that includes:
Opioid medication for chronic pain
Anti-coagulants
Any heart medications
Daily medication for asthma
Medical Exclusion Criteria
General Exclusion
Primary purpose
Allocation
Interventional model
Masking
38 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal